MeSH D002494 - central nervous system infections
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D002494:Â
Central nervous system infections
D000069544:Infectious encephalitis
0 Companies
0 Drugs
Success rate
D001922:Brain abscess
0 Companies
0 Drugs
Success rate
D004679:Encephalomyelitis
0 Companies
0 Drugs
Success rate
D008590:Meningoencephalitis
0 Companies
0 Drugs
Success rate
D009187:Myelitis
0 Companies
0 Drugs
Success rate
D017096:Prion diseases
0 Companies
0 Drugs
Success rate
D020314:Central nervous system fungal infections
0 Companies
0 Drugs
Success rate
D020802:Epidural abscess
0 Companies
0 Drugs
Success rate
D020805:Central nervous system viral diseases
0 Companies
0 Drugs
Success rate
D020806:Central nervous system bacterial infections
0 Companies
0 Drugs
Success rate
D020807:Central nervous system parasitic infections
0 Companies
0 Drugs
Success rate
D020819:Perimeningeal infections
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Tobramycin | Tobramycin |  | 1992-01-30 |  |  |
| Padagis | Dexamethasone, Tobramycin | Tobramycin Dexamethasone |  | 2022-02-11 |  |  |
| Viatris | Tobramycin | Tobi |  | 1997-12-22 |  |  |
| Mylan | Tobramycin | Tobramycin |  | 2008-03-11 |  |  |
| Lupin Research | Tobramycin | Tobramycin |  | 2017-03-22 |  |  |
| Sandoz | Tobramycin | Tobrex |  | 1984-12-13 |  |  |
| Dexamethasone, Tobramycin | Tobradex |  | 1988-08-18 |  |  | |
| Novartis | Dexamethasone, Tobramycin | Tobradex |  | 1988-09-28 |  |  |
| Tobramycin | Tobrex |  | 1982-01-01 |  |  |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/0
Phase 3
100%3/3
Approved: 3Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use